Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19.

Leung, Elizabeth; Crass, Ryan L; Jorgensen, Sarah C J; Raybardhan, Sumit; Langford, Bradley J; Moore, W Justin; Rhodes, Nathaniel J

Leung, Elizabeth; Crass, Ryan L; Jorgensen, Sarah C J; Raybardhan, Sumit; Langford, Bradley J; Moore, W Justin; Rhodes, Nathaniel J.

Afiliação

Leung E; Department of Pharmacy, St. Michael's Hospital/Unity Health Toronto, Toronto, ON, Canada. beth.leung@utoronto.ca.
Crass RL; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada. beth.leung@utoronto.ca.
Jorgensen SCJ; Li Ka Shing Knowledge Institute, Toronto, ON, Canada. beth.leung@utoronto.ca.
Raybardhan S; Ann Arbor Pharmacometrics Group, Ann Arbor, MI, USA.
Langford BJ; Department of Pharmacy, Mount Sinai Hospital, Toronto, ON, Canada.
Moore WJ; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
Rhodes NJ; Department of Pharmacy, North York General, Toronto, ON, Canada.

Clin Pharmacokinet ; 61(2): 155-165, 2022 02.

Article em En | MEDLINE | ID: mdl-34894345

Assuntos

Tratamento Farmacológico da COVID-19; Anticorpos Monoclonais Humanizados; Humanos; SARS-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tratamento Farmacológico da COVID-19 Limite: Humans Idioma: En Revista: Clin Pharmacokinet Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google